Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2024
-
- participants needed
- 50
-
- sponsor
- M.D. Anderson Cancer Center
Summary
This phase II trial studies how well ultra low dose radiation therapy works in treating patients with mycosis fungoides. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ultra low doses of radiation may help control the disease and reduce side effects compared to treatment with higher doses.
Description
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of low dose radiation in the management of cutaneous mycosis fungoides (MF), measured as any local control for each lesion at 12 (+/- 2) weeks after the treatment, in patients with stage IA - IVB cutaneous MF.
SECONDARY OBJECTIVES:
I. To evaluate complete response (CR) rates at 12 (+2) weeks and beyond.
II. To evaluate the persistence of response (CR, partial response [PR], stable disease, or progressive disease) in the treated lesion beyond 12 (+2) weeks.
III. To evaluate overall survival.
IV. To evaluate progression free survival.
V. To evaluate patient symptom relief.
VI. To evaluate the toxicity of radiation to the skin.
VII. To assess if number of previous therapies including chemotherapy, targeted therapy, topical therapy, or total skin radiation affects the response.
VIII. To characterize the microbiome of mycosis fungoides patient within both the lesion and unaffected skin.
IX. To characterize shifts in the microbiome that occur after radiation therapy.
- OUTLINE
Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
After completion of study treatment, patients are followed up at 4-6 and 10-14 weeks, every 3 months for 6-8 months, then every 6-12 months for up to 2 years.
Details
| Condition | Localized Skin Lesion, Mycosis Fungoides |
|---|---|
| Treatment | radiation therapy, questionnaire administration, quality-of-life assessment, Symptom questionnaire, Photographs, Microbiome Analysis |
| Clinical Study Identifier | NCT03398161 |
| Sponsor | M.D. Anderson Cancer Center |
| Last Modified on | 25 May 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer